Ova donors demand compensation from government
By Asia News,
AsiaNews.it
| 02. 07. 2006
Seoul (AsiaNews) _ A coalition of 35 women_s groups filed a suit for compensation against the South Korean government on behalf of women suffering from side-effects after making uninformed ova donations to Prof Hwang Woo-suk for his research on stem cell embryos.
The women_s groups in association with Lawyers for a Democratic Society (Minbyun) claim that the donors who provided the _research material_ to the now disgraced researcher received no information on the side effects of excessive ova collection.
During the investigation into the fraudulent study, it was found that Hwang_s team used 2,221 ova, about fivefold the number Hwang had previously claimed, and that about 20 per cent of the donors have suffered side-effects from this invasive practice.
_Fifteen women donated eggs more than twice. The Mizmedi Hospital team even collected ova twice from a woman, who was hospitalized for side-effects after each donation,__ the women_s groups said in a statement. _It is an example of how the embryonic stem cell research, which received full national support, trampled on women_s human rights,_ the press release also said.
The groups...
Related Articles
By Priyanka Runwal, Chemical and Engineering News | 08.05.2024
Saritee Sanodiya, 26, has spent countless days wondering if she’ll ever live a “normal” life. Growing up, Sanodiya often missed school, frequenting the hospital for sudden, life-threatening drops in her hemoglobin levels and excruciating pain in her joints. High fever...
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024